On a roll, Novo's star obesity drug Wegovy shows benefits in patients with heart failure

Just a few short weeks after Wegovy posted a major cardio outcomes win, Novo Nordisk has chalked up another heart-related victory for its semaglutide star.

In the phase 3 study STEP HFpEF, semaglutide 2.4 mg (Wegovy’s dose) bested placebo at reducing symptoms and physical limitations in patients with obesity and heart failure with preserved ejection fraction (HFpEF).